Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio s Q3 Revenue Rises, Net Income Falls

NEW YORK, Nov. 4 (GenomeWeb News) - Harvard Bioscience yesterday reported a 4-percent increase in third-quarter revenues and a 31-percent drop in net income.


For the quarter ended Sept. 30, the company's apparatus and instrumentation unit, which it is retaining, brought in revenue of $17.2 million for the quarter, up from $16.5 million in the prior-year period.


Harvard Bio did not disclose revenue for its capital equipment segment, which it plans to divest and has classified as discontinued operations held for sale.


The company posted net income of $661,000 for the third quarter, down from $957,000 in the year-ago period.


Research and development expenses fell by 14 percent to $700,000 for the quarter from $800,000 in the same period of 2004.


The company ended the quarter with cash and cash equivalents of $11.3 million.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.